Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

Jiangsu Kanion Pharmaceutical Co.,Ltd. (600557.SS)

Compare
13.87
-0.70
(-4.80%)
At close: April 3 at 3:00:01 PM GMT+8
Loading Chart for 600557.SS
  • Previous Close 14.57
  • Open 14.10
  • Bid 13.87 x --
  • Ask 13.88 x --
  • Day's Range 13.68 - 14.10
  • 52 Week Range 11.77 - 21.58
  • Volume 20,654,655
  • Avg. Volume 8,711,968
  • Market Cap (intraday) 7.898B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 20.40
  • EPS (TTM) 0.68
  • Earnings Date --
  • Forward Dividend & Yield 0.37 (2.68%)
  • Ex-Dividend Date May 31, 2024
  • 1y Target Est --

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 and is based in Lianyungang, China.

www.kanion.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600557.SS

View More

Performance Overview: 600557.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600557.SS
1.84%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

600557.SS
32.43%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

600557.SS
3.49%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

600557.SS
9.36%
SSE Composite Index (000001.SS)
20.91%

Compare To: 600557.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600557.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    8.30B

  • Enterprise Value

    6.06B

  • Trailing P/E

    20.40

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.05

  • Price/Book (mrq)

    1.75

  • Enterprise Value/Revenue

    1.45

  • Enterprise Value/EBITDA

    9.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.05%

  • Return on Assets (ttm)

    3.44%

  • Return on Equity (ttm)

    7.55%

  • Revenue (ttm)

    3.9B

  • Net Income Avi to Common (ttm)

    391.86M

  • Diluted EPS (ttm)

    0.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.24B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    664.74M

Research Analysis: 600557.SS

View More

Company Insights: 600557.SS

Research Reports: 600557.SS

View More

People Also Watch